Request Trial
vchal
vchal / iStockphoto.com
17 January 2018Europe

Broad Institute to appeal CRISPR patent revocation

The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office (EPO) to revoke one of its patents covering CRISPR/Cas9 technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
UPC hands Occlutech second win against Chinese medtech company in a month
19 June 2026   The court overturns a decision granting the German-based company provisional measures and ordering a Chinese medtech rival to stop selling its device in four European countries.
Europe
Exclusive: ‘Cultural differences are an asset’ at the UPC
16 June 2026   In the second of a series of interviews with women judges at the pan-European court, Ulrike Voß talks to Sarah Speight about her career, her views on the court so far, and how more women could be encouraged to join the judiciary.
Europe
Siemens ordered to recall mammography device across European countries
11 June 2026   The UPC has dealt Siemens a loss against a rival US medtech company, upholding a key breast imaging patent and addressing a range of issues from infringement and validity to recall orders and software-based workarounds.


Editor's picks

Hikma v Amarin: Six takeaways from the pivotal ruling
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

Editor's picks

Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

More features

UPC hands Occlutech second win against Chinese medtech company in a month
US life sciences damages averaged $33.5m between 2019-2025
Quantum and photonics tech licensing expert joins EIP
Court upholds $83m sequencing verdict and sets royalty rate
Exclusive: ‘Cultural differences are an asset’ at the UPC
Amgen and subsidiary dealt $20m blow over rodent antibody tech
Ex-Simmons head of IP joins Carpmaels & Ransford
Moderna: BioNTech is claiming work ‘it never did’